These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 9080496)

  • 1. Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.
    Kurita T; Ohe T; Shimizu W; Suyama K; Aihara N; Takaki H; Kamakura S; Shimomura K
    Pacing Clin Electrophysiol; 1997 Mar; 20(3 Pt 1):695-705. PubMed ID: 9080496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
    Johansson M; Carlsson L
    J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
    Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
    Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological and pathological responses of TU waves to class Ia antiarrhythmic drugs.
    Maruyama T; Ohe T; Kurita T; Aihara N; Shimizu W
    Eur Heart J; 1995 May; 16(5):667-73. PubMed ID: 7588899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiarrhythmic drugs and torsade de pointes.
    Lazzara R
    Eur Heart J; 1993 Nov; 14 Suppl H():88-92. PubMed ID: 8293758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe respiratory failure and torsades de pointes induced by disopyramide in a patient with myasthenia gravis.
    Hirose K; Yamaguchi H; Oshima Y; Choraku M; Hirono A; Takamori N; Tamura K
    Intern Med; 2008; 47(19):1703-8. PubMed ID: 18827420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide-induced long QT and torsades de pointes.
    Aktas MK; Shah AH; Akiyama T
    Ann Noninvasive Electrocardiol; 2007 Jul; 12(3):197-202. PubMed ID: 17617063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
    van Opstal JM; Schoenmakers M; Verduyn SC; de Groot SH; Leunissen JD; van Der Hulst FF; Molenschot MM; Wellens HJ; Vos MA
    Circulation; 2001 Nov; 104(22):2722-7. PubMed ID: 11723026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.
    Morganroth J
    Am J Cardiol; 1993 Aug; 72(6):10B-13B. PubMed ID: 8256748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monophasic action potentials in patients with torsades de pointes.
    Miwa S; Inoue T; Yokoyama M
    Jpn Circ J; 1994 Apr; 58(4):248-58. PubMed ID: 8051783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization.
    Carlsson L; Abrahamsson C; Drews L; Duker G
    Circulation; 1992 Apr; 85(4):1491-500. PubMed ID: 1555289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary acetylcholine-induced prolongation of the QT interval and Torsade des Pointes in long QT interval syndrome.
    Aizawa Y; Matsubara T; Higuchi K; Washizuka T; Tamura Y; Uchiyama H; Igarashi Y; Shibata A
    Jpn Heart J; 1994 Sep; 35(5):683-8. PubMed ID: 7830332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced torsades de pointes and implications for drug development.
    Fenichel RR; Malik M; Antzelevitch C; Sanguinetti M; Roden DM; Priori SG; Ruskin JN; Lipicky RJ; Cantilena LR;
    J Cardiovasc Electrophysiol; 2004 Apr; 15(4):475-95. PubMed ID: 15090000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsades de pointes due to drug interaction between disopyramide and clarithromycin.
    Choudhury L; Grais IM; Passman RS
    Heart Dis; 1999; 1(4):206-7. PubMed ID: 11720625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental models of torsades de pointes.
    Weissenburger J; Davy JM; Chézalviel F
    Fundam Clin Pharmacol; 1993; 7(1):29-38. PubMed ID: 8458600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide.
    Asajima H; Saito N; Ohmura Y; Ohmura K
    Eur J Clin Pharmacol; 2012 Mar; 68(3):331-3. PubMed ID: 21898101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.